Core Viewpoint - The company, Zai Lab Limited, announced the publication of exploratory Phase 2 clinical trial results for its core product, Tzenglongtinib, targeting cholangiocarcinoma in a high-impact medical journal [1] Group 1: Clinical Trial Details - The Phase 2 study (NCT04919642) is an open-label, multicenter trial involving eligible cholangiocarcinoma patients with FGFR2 fusions and primary or acquired resistance to FGFR inhibitors [1] - The study also includes patients with other FGFR gene alterations and those with wild-type FGFR [1] Group 2: Drug Efficacy - Tzenglongtinib demonstrates the ability to overcome acquired resistance to FGFR inhibitors in patients with FGFR2 fusion-positive cholangiocarcinoma [1] - The drug shows anti-tumor activity in cholangiocarcinoma patients with other FGFR gene alterations [1]
药捷安康-B(02617)发表核心产品替恩戈替尼针对胆管癌的探索性临床结果